Screening for cervical cancer: A modeling study for the us preventive services task force

  • Kulasingam S
  • Havrilesky L
  • Ghebre R
 et al. 
  • 3

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

OBJECTIVE: This study addresses the following 3 questions posed by the US Preventive Services Task Force: (1) at what age should screening for cervical cancer begin; (2) at what age should screening for cervical cancer end; and (3) how do the benefits and potential harms of screening strategies that use human papillomavirus DNA testing in conjunction with cytology (cotesting) compare with those strategies that use cytology only? MATERIALS AND METHODS: A Markov model was updated and used to quantify clinical outcomes (i.e., colposcopies, cancers, and life expectancy) associated with different screening strategies. RESULTS: Screening in the teenaged years is associated with a high number of colposcopies (harms), small differences in cancers detected and, as a result, small gains in life expectancy (benefits). Screening women beginning in the early 20s provides a reasonable balance of the harms and benefits of screening. Among women who have been screened according to the current recommendations for cervical cancer (beginning at age 21 years and conducted every 3 years with cytology), screening beyond 65 years is associated with small additional gains in life expectancy but large increases in colposcopies. For cotesting, a strategy of cytology only conducted every 3 years, followed by cotesting conducted every 5 years (for women >=30 years), is associated with fewer colposcopies and greater gains in life expectancy compared with screening with cytology only conducted every 3 years. CONCLUSIONS: The results of this modeling study support current US Preventive Services Task Force recommendations for cervical cancer screening. 2013, American Society for Colposcopy and Cervical Pathology.

Author-supplied keywords

  • *cancer screening
  • *hidden Markov model
  • *uterine cervix cancer/di [Diagnosis]
  • Wart virus
  • adolescent
  • adult
  • article
  • cancer cytodiagnosis
  • cancer mortality
  • colposcopy
  • false positive result
  • female
  • human
  • life expectancy
  • outcome assessment
  • papillomavirus infection/di [Diagnosis]
  • quantitative analysis
  • sensitivity and specificity
  • uterine cervix biopsy
  • uterine cervix carcinoma in situ/di [Diagnosis]
  • virus DNA
  • virus diagnosis

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • S.L. Kulasingam

  • L.J. Havrilesky

  • R. Ghebre

  • E.R. Myers

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free